1
|
Feredj E, Wiedemann A, Krief C, Maitre B, Derumeaux G, Chouaid C, Le Corvoisier P, Lacabaratz C, Gallien S, Lelièvre JD, Boyer L. Immune response to pertussis vaccine in COPD patients. Sci Rep 2023; 13:11654. [PMID: 37468500 DOI: 10.1038/s41598-023-38355-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 07/06/2023] [Indexed: 07/21/2023] Open
Abstract
Exacerbation triggered by respiratory infection is an important cause of morbidity and mortality in chronic obstructive pulmonary disease (COPD) patients. Strategies aiming to preventing infection may have significant public health impact. Our previous study demonstrated decreased immunological response to seasonal flu vaccination in COPD patients, questioning the efficiency of other vaccines in this group of patients. We performed a prospective, monocenter, longitudinal study that evaluated the humoral and cellular responses upon pertussis vaccination. We included 13 patients with stable COPD and 8 healthy volunteers. No difference in circulating B and T cell subsets at baseline was noted. Both groups presented similar levels of TFH, plasmablasts and pertussis specific antibodies induction after vaccination. Moreover, monitoring T cell immunity after ex-vivo peptide stimulation revealed equivalent induction of functional and specific CD4+ T cells (IFNγ, TNFα and IL-2-expressing T cells) in both groups. Our results highlight the immunological efficiency of pertussis vaccination in this particularly vulnerable population and challenge the concept that COPD patients are less responsive to all immunization strategies. Healthcare providers should stress the necessity of decennial Tdap booster vaccination in COPD patients.
Collapse
Affiliation(s)
- E Feredj
- Infectious Disease Department, AP-HP (Assistance Publique-Hôpitaux de Paris), Groupe Hospitalier Henri-Mondor/Albert Chenevier, 94010, Créteil, France.
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France.
| | - A Wiedemann
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France
- Vaccine Research Institute, 94010, Créteil, France
| | - C Krief
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France
- Vaccine Research Institute, 94010, Créteil, France
| | - B Maitre
- Department of Physiology, APHP, Hôpital Henri Mondor, 94010, Créteil, France
- Department of Pulmonology, Centre Hospitalier Intercommunal, 94010, Créteil, France
| | - G Derumeaux
- Department of Physiology, APHP, Hôpital Henri Mondor, 94010, Créteil, France
| | - C Chouaid
- Department of Pulmonology, Centre Hospitalier Intercommunal, 94010, Créteil, France
| | - P Le Corvoisier
- INSERM, Clinical Investigation Center 1430, Hôpital Henri Mondor, 94010, Créteil, France
| | - C Lacabaratz
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France
- Vaccine Research Institute, 94010, Créteil, France
| | - S Gallien
- Infectious Disease Department, AP-HP (Assistance Publique-Hôpitaux de Paris), Groupe Hospitalier Henri-Mondor/Albert Chenevier, 94010, Créteil, France
- EA Dynamyc, Université Paris Est Créteil-École Vétérinaire de Maison Alfort, 94000, Créteil, France
| | - J D Lelièvre
- Infectious Disease Department, AP-HP (Assistance Publique-Hôpitaux de Paris), Groupe Hospitalier Henri-Mondor/Albert Chenevier, 94010, Créteil, France
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France
- Vaccine Research Institute, 94010, Créteil, France
| | - L Boyer
- INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France
- Department of Physiology, APHP, Hôpital Henri Mondor, 94010, Créteil, France
| |
Collapse
|
2
|
Molino D, Durier C, Radenne A, Desaint C, Ropers J, Courcier S, Vieillard LV, Rekacewicz C, Parfait B, Appay V, Batteux F, Barillot E, Cogné M, Combadière B, Eberhardt CS, Gorochov G, Hupé P, Ninove L, Paul S, Pellegrin I, van der Werf S, Lefebvre M, Botelho-Nevers E, Ortega-Perez I, Jaspard M, Sow S, Lelièvre JD, de Lamballerie X, Kieny MP, Tartour E, Launay O. A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project. Nat Med 2022; 28:882-884. [PMID: 35513532 DOI: 10.1038/s41591-022-01785-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Diana Molino
- Université Paris Cité, National Institute for Health and Medical Research (INSERM) CIC 1417 Cochin Pasteur, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | | | - Anne Radenne
- AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
| | | | - Jacques Ropers
- AP-HP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Unité de Recherche Clinique des Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
| | - Soizic Courcier
- Université Paris Cité, National Institute for Health and Medical Research (INSERM) CIC 1417 Cochin Pasteur, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | - Louis Victorien Vieillard
- Université Paris Cité, National Institute for Health and Medical Research (INSERM) CIC 1417 Cochin Pasteur, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | - Claire Rekacewicz
- Université Paris Cité, National Institute for Health and Medical Research (INSERM) CIC 1417 Cochin Pasteur, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France
| | - Beatrice Parfait
- AP-HP, Hôpital Cochin, Fédération des Centres de Ressources Biologiques-Plateforme de Ressources Biologiques Centre de Ressources Biologique Cochin, Paris, France
| | - Victor Appay
- Centre Hospitalier Universitaire (CHU) Bordeaux, Laboratory of Immunology and Immunogenetics, Université de Bordeaux, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5164, INSERM ERL 1303, ImmunoConcEpT, Bordeaux, France
| | - Frédéric Batteux
- AP-HP, Hôpital Cochin, Service d'Immunologie Biologique et Plateforme d'Immunomonitoring Vaccinal, Paris, France
| | - Emmanuel Barillot
- Institut Curie, PSL Research University-INSERM U900-MINES ParisTech, PSL, Paris, France
| | - Michel Cogné
- Laboratory of Immunology-Research Unit INSERM U 1236, B cell Ig Remodelling Singularities (BIGRES), Faculty of Medicine, French Blood Center (EFS Bretagne) & University Hospital, Rennes, France
| | - Béhazine Combadière
- Centre d'Immunologie et des Maladies Infectieuses-Paris (Cimi-Paris), INSERM U1135, Sorbonne Université, Paris, France
| | - Christiane S Eberhardt
- University of Geneva, Faculty of Medicine, Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine and Center for Vaccinology, Geneva, Switzerland
| | - Guy Gorochov
- Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Département d'Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
| | - Philippe Hupé
- Institut Curie, PSL Research University-INSERM U900-MINES ParisTech, PSL, Paris, France.,CNRS, UMR 144, Paris, France
| | - Laetitia Ninove
- Aix Marseille Université, Research Institute for Sustainable Development (IRD) 190, INSERM 1207, IHU Méditerranée Infection, Unité des Virus Émergents, Marseille, France
| | - Stéphane Paul
- INSERM, U1111, CNRS, UMR 530, Immunology and Immunomonitoring Laboratory, iBiothera, CIRI-GIMAP, UCBL 1, UJM, CIC 1408, Saint-Etienne, France
| | - Isabelle Pellegrin
- Centre Hospitalier Universitaire (CHU) Bordeaux, Laboratory of Immunology and Immunogenetics, Université de Bordeaux, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 5164, INSERM ERL 1303, ImmunoConcEpT, Bordeaux, France
| | - Sylvie van der Werf
- Université Paris Cité, Institut Pasteur, Unité Génétique Moléculaire Virus à ARN UMR 3569 CNRS, Paris, France
| | - Maeva Lefebvre
- CHU de Nantes, INSERM CIC1413, Maladies Infectieuses et Tropicales, Centre de Prévention des Maladies Infectieuses et Transmissibles, Nantes, France
| | - Elisabeth Botelho-Nevers
- INSERM CIC 1408, Axe Vaccinologie, CHU de Saint-Etienne, Service d'Infectiologie, Saint-Etienne, France
| | | | - Marie Jaspard
- The Alliance for International Medical Action (ALIMA), Paris, France.,University of Bordeaux, INSERM, IRD, Bordeaux Population Health Center, UMR 1219, Bordeaux, France
| | - Samba Sow
- The Center for Vaccine Development, Bamako, Mali
| | | | - Xavier de Lamballerie
- Aix Marseille Université, Research Institute for Sustainable Development (IRD) 190, INSERM 1207, IHU Méditerranée Infection, Unité des Virus Émergents, Marseille, France
| | | | - Eric Tartour
- AP-HP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Paris, France
| | - Odile Launay
- Université Paris Cité, National Institute for Health and Medical Research (INSERM) CIC 1417 Cochin Pasteur, Innovative Clinical Research Network in Vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France.
| |
Collapse
|
4
|
Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300. [PMID: 22550117 PMCID: PMC3381639 DOI: 10.1093/cid/cis383] [Citation(s) in RCA: 174] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. METHODS We performed a randomized placebo-controlled dose escalation (10, 20 and 30 µg/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/µL and plasma HIV levels <50 copies/mL. Toxicity, activity and the impact of rhIL-7 on immune reconstitution were monitored. RESULTS Doses of rhIL-7 up to 20 µg/kg were well tolerated. CD4 increases of predominantly naive and central memory T cells were brisk (averaging 323 cells/µL at 12 weeks) and durable (up to 1 year). Increased cell cycling and transient increased bcl-2 expression were noted. Expanded cells did not have the characteristics of regulatory or activated T cells. Transient low-level HIV viremia was seen in 6 of 26 treated patients; modest increases in total levels of intracellular HIV DNA were proportional to CD4 T-cell expansions. IL-7 seemed to increase thymic output and tended to improve the T-cell receptor (TCR) repertoire in persons with low TCR diversity. CONCLUSIONS Three weekly doses of rhIL-7 at 20 µg/kg are well tolerated and lead to a dose-dependent CD4 T-cell increase and the broadening of TCR diversity in some subjects. These data suggest that this rhIL-7 dose could be advanced in future rhIL-7 clinical studies. CLINICAL TRIALS REGISTRATION NCT0047732.
Collapse
|
6
|
Lelièvre JD, Mammano F, Arnoult D, Petit F, Grodet A, Estaquier J, Ameisen JC. A novel mechanism for HIV1-mediated bystander CD4+ T-cell death: neighboring dying cells drive the capacity of HIV1 to kill noncycling primary CD4+ T cells. Cell Death Differ 2004; 11:1017-27. [PMID: 15118766 DOI: 10.1038/sj.cdd.4401441] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
CD4+ T-cell death is a crucial feature of AIDS pathogenesis, but the mechanisms involved remain unclear. Here, we present in vitro findings that identify a novel process of HIV1 mediated killing of bystander CD4+ T cells, which does not require productive infection of these cells but depends on the presence of neighboring dying cells. X4-tropic HIV1 strains, which use CD4 and CXCR4 as receptors for cell entry, caused death of unstimulated noncycling primary CD4+ T cells only if the viruses were produced by dying, productively infected T cells, but not by living, chronically infected T cells or by living HIV1-transfected HeLa cells. Inducing cell death in HIV1-transfected HeLa cells was sufficient to obtain viruses that caused CD4+ T-cell death. The addition of supernatants from dying control cells, including primary T cells, allowed viruses produced by living HIV1-transfected cells to cause CD4+ T-cell death. CD4+ T-cell killing required HIV1 fusion and/or entry into these cells, but neither HIV1 envelope-mediated CD4 or CXCR4 signaling nor the presence of the HIV1 Nef protein in the viral particles. Supernatants from dying control cells contained CD95 ligand (CD95L), and antibody-mediated neutralization of CD95L prevented these supernatants from complementing HIV1 in inducing CD4+ T-cell death. Our in vitro findings suggest that the very extent of cell death induced in vivo during HIV1 infection by either virus cytopathic effects or immune activation may by itself provide an amplification loop in AIDS pathogenesis. More generally, they provide a paradigm for pathogen-mediated killing processes in which the extent of cell death occurring in the microenvironment might drive the capacity of the pathogen to induce further cell death.
Collapse
Affiliation(s)
- J D Lelièvre
- EMI-U 9922 INSERM/Université Paris 7, IFR02, AP-HP, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France.
| | | | | | | | | | | | | |
Collapse
|